INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2013

High-dose intravenous ascorbic acid was well tolerated in advanced cancer patients, but no objective antitumor responses were observed.

Five cohorts of three patients with advanced solid tumors received intravenous ascorbic acid at 1 g/min for 4 consecutive days per week for 4 weeks, starting at 30 g/m² with 20 g/m² dose escalations. Ascorbic acid was eliminated by first-order kinetics with a half-life of 2.0 ± 0.6 h and clearance of 21 ± 5 dL/h m². Cmax and AUC increased with dose up to 70 g/m² (reaching 49 mM and 220 h mM, respectively). All doses were well tolerated, but no patient demonstrated an objective antitumor response.

Study type
Phase I dose-escalation clinical trial
Who was studied
15 patients with advanced solid tumors refractory to standard therapy (5 cohorts of 3 patients)
What was measured
Safety, tolerability, pharmacokinetics, and objective antitumor response

THE PAPER

Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer.

Stephenson CM, Levin RD, Spector T, Lis CG. Cancer Chemother Pharmacol, 2013.

PubMed 23670640 ↗DOI 10.1096/fj.07-9574lsf ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.